Share this article

 Email

 Print

 

Republish this article

The text of this article by Futurity is licensed under a Creative Commons Attribution-No Derivatives License.

More
Health & Medicine

Lower obesity rates for kids in traditional families

Daily calcium linked to longer life in women

Drug blunts cocaine addiction in mice

Where visual search happens in the brain

Childhood CT scans slightly raise cancer risk

Polio virus engineered to kill brain tumor

Cartilage gets bum rap for osteoarthritis

How to decide if a daily aspirin is harmful

Anxiety drug reduces MS symptoms in mice

The study, led by University of Melbourne researcher Rob Hester and his colleagues at the Queensland Brain Institute, investigated how the brain monitors ongoing behavior for performance errors—specifically failures of impulse control.

It found that a single dose of Ritalin (methylphenidate) results in significantly greater activity in the brain’s error monitoring network and improved volunteers’ awareness of their mistakes.

Diminished awareness of performance errors limits the extent to which humans correct their behavior and has been linked to loss of insight in a number of clinical syndromes, including Alzheimer’s disease, schizophrenia, and attention-deficit hyperactivity disorder.

Published in the Journal of Neuroscience, the findings demonstrate that activity within those parts of the brain that deal with human error, including the dorsal anterior cingulate (dACC) and inferior parietal lobule (IPL) differs depending on whether participants are aware of their performance errors.

Critically, researchers showed that a single, clinically relevant dose of methylphenidate, which works by increasing the levels of catecholamines in the brain, dramatically improved error awareness in healthy adults.

Researchers used functional magnetic resonance imaging (fMRI) to show that methylphenidate was able to promote the conscious awareness of performance errors by strengthening activation differences within the dACC and IPL for errors made with and without awareness, compared to placebo and other comparison drugs.

While the study provided only a single dose of methylphenidate to healthy participants, and needed to be replicated in people using standard clinical doses, the data highlights the potential of pharmacotherapy in addressing problems of awareness and insight that feature in a range of neurologic and psychiatric conditions.

Hester says failure to recognize errors was related to poor insight into a person’s clinical condition, which can impair treatment.

“For example, in conditions such as schizophrenia and Alzheimer’s disease, poor error awareness has been associated with delusions, paranoia, and has been the cause of considerable distress to patients,” he says.

“Failing to recognize your own error at the time can account for the difference between your recollection and the reality that confronts you. Understanding the brain mechanisms that underlie how we become conscious of our mistakes is an important first step in improving error awareness, and potentially reducing these symptoms.”

More news from the University of Melbourne: http://newsroom.melbourne.edu/